VC CELL THERAPY
VC Cell Therapy is engaged in the research and development of technology related to regenerative medicine. It also develops robots and artificial intelligence for cell production and conducts research on the transplantation of pigment epithelial cells for regenerating retinal cells affected due to retinal degenerative diseases, enabling healthcare professionals to improve the treatments provided to patients.
VC CELL THERAPY
Industry:
Health Care Medical Pharmaceutical
Founded:
2021-03-08
Address:
Kobe, Kyoto, Japan
Country:
Japan
Website Url:
http://www.vcct.jp
Status:
Active
Total Funding:
600 M JPY
Technology used in webpage:
Euro CrUX Top 50m CrUX Dataset Pound Sterling Japanese Yen
Similar Organizations
Addpharma
Addpharma is a pharmaceuticals company that develops Incrementally Modified Drugs (IMDs).
Eden Biologics
Eden Biologics is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners.
MedGrocer
MedGrocer is a pharmaceutical company that delivers prescription and OTC medicines.
MediCane Health
MediCane Health is a pharmaceutical company that provides innovative and high-quality Medical Cannabis medications to patients.
Pristine Pearl Pharma
Pristine Pearl Pharma is a pharmaceutical company that provides cardiology and diabetology medicines.
Sunshine Guojian Pharmaceutical Shanghai
Sunshine Guojian Pharmaceutical Shanghai is a biopharmaceutical company that provides antibody drugs.
Trevarx Biomedical
Trevarx Biomedical is a biomedical startup that develops new radiopharmaceuticals.
Investors List
Dai-Dan
Dai-Dan investment in Venture Round - VC Cell Therapy
Sysmex Corporation
Sysmex Corporation investment in Venture Round - VC Cell Therapy
YASKAWA Electric
YASKAWA Electric investment in Venture Round - VC Cell Therapy
YASKAWA Electric
YASKAWA Electric investment in Venture Round - VC Cell Therapy
Official Site Inspections
http://www.vcct.jp
- Host name: www3007.sakura.ne.jp
- IP address: 49.212.207.17
- Location: Osaka Japan
- Latitude: 34.6848
- Longitude: 135.5142
- Timezone: Asia/Tokyo
- Postal: 543-0062
More informations about "VC Cell Therapy"
About | 株式会社 VC Cell Therapy - vcct.jp
VCCT USA inc. －Date of establishment: June 24, 2024 －Location: 500 La Terraza Blvd Suite 150 Escondido, CA 92025 USA ... European Molecular Biology Organization (EMBO) Masayo …See details»
HOME | 株式会社 VC Cell Therapy
2017年12月、弊社代表の高橋政代の提唱するアイセンター構想を具現化した神戸アイセンターが設立されました。 神戸アイセンターは、再生医療の研究施設、最先端の眼科医療施設、社 …See details»
VC Cell Therapy - Crunchbase Company Profile
VC Cell Therapy is engaged in the research and development of technology related to regenerative medicine. It also develops robots and artificial …See details»
VCCT Company Profile - Office Locations, Competitors ... - Craft
VCCT (株式会社 VC Cell Therapy) is a biotechnology company that develops regenerative cell therapy solutions for the treatment of retinal diseases. It develops techniques to induce and …See details»
VCCT Inc., Leading the Field of Retinal Regeneration
Nov 24, 2023 VCCT is a seed/growth-stage biotechnology company developing a portfolio of ex vivo and in vivo cell therapy solutions for ocular diseases. We are a proud member of the Kobe Eye Center Initiative, a consortium of …See details»
VCCT INC. Company Profile | KOBE, HYOGO, Japan | Competitors ...
Find company research, competitor information, contact details & financial data for VCCT INC. of KOBE, HYOGO. Get the latest business insights from Dun & Bradstreet. D&B Business …See details»
VCCT Inc. - VentureRadar
VC Cell Therapy (VCCT) conducts research and development in the fields of ophthalmology and regenerative medicine. Established in March 2021 as a subsidiary of the company Vision Care …See details»
Science | 株式会社 VC Cell Therapy - vcct.jp
With the outcome of these clinical studies, VCCT will bring the therapy as early as possible to patients eagerly waiting for the new therapy. What is the Retinal Pigment Epithelium (RPE)? The Retinal Pigment Epithelium (RPE) is a single …See details»
VCCT | Top Biotech Startup in Japan-2022
VCCT has successfully concluded its latest fundraising round, amassing a total of 1.7 billion yen ($11.3 million USD) in funds. This includes 800 million yen ($5.3 million USD) from convertible bonds and around 300 million yen ($2 million …See details»
「自家iPS細胞由来網膜細胞移植による網膜疾患治療法 …
Oct 15, 2021 株式会社VC Cell Therapy（VCCT）について. VCCTは、再生医療等に関する技術の研究及び開発、物品の製造、販売、知的財産の取得、保有、使用許諾、譲渡及び管理を目的に、眼科領域・再生医療領域における研究・開 …See details»
VCCT Inc. - BIO International Convention | BIO
The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... The VCCT's products have …See details»
株式会社VC Cell Therapy - スピーダ スタートアップ情報 ...
Oct 16, 2024 iPS細胞を用いて視細胞と網膜色素上皮（RPE）細胞を誘導・増殖する技術の開発。 ロボットやAIを用いた細胞製造プロセスの構築。 「すべての患者さんのために、あらゆ …See details»
VC Cell Therapy - STARTUP DB｜スタートアップデータベース
網膜変性疾患をターゲットとした“ゲノム編集iPS細胞由来RPE細胞”「MastCT-03」などの開発を行うスタートアップ。 「MastCT-03」は、iPS 細胞から作製した RPE 細胞を細⻑い紐状に …See details»
www.vcct.jp
Www.vcct.jpSee details»
網膜再生医療をリードするVC Cell Therapy、6億円の資金調達を …
Nov 15, 2023 社名：株式会社VC Cell Therapy（VCCT） 資金調達額：約6億円 引受先：シスメックス株式会社、ダイダン株式会社、株式会社安川電機 累計資金調達額：約17億円 本社所 …See details»
J-TECとVCCT、iPS再生医療実用化へ提携／第一三共、抗TA …
Jan 14, 2025 J-TECの畠賢一郎社長（左）とVCCTの高橋政代社長 . J-TECとVC Cell Therapyが資本業務提携…網膜変性向けiPS再生医療、実用化加速. ジャパン・ティッシュエンジニアリ …See details»
Japan Tissue Engineering and VCCT Inc. Form a Capital and …
Jan 14, 2025 outsourced as it is brought to market, VCCT will give preferential negotiating rights to J-TEC for a certain period of time. (2) Based on this alliance agreement, J-TEC will offer …See details»
iPS細胞による網膜再生医療を牽引する株式会社VC Cell Therapy …
株式会社VC Cell Therapy(代表取締役社長：高橋 政代※、以下 VCCT)は、シスメックス株式会社(代表取締役社長：浅野 薫)、ダイダン株式会社(代表取締役社長：藤澤 一郎)および株式会社 …See details»
VC Cell Therapy、他家iPS細胞由来RPE細胞の製品化などでJ-TECと …
VC Cell Therapy（神戸市、高橋政代代表取締役社長、以下VCCT）とジャパン・ティッシュエンジニアリング（J-TEC）は2025年1月14日、資本業務提携を行うと発表した。VCCTが開発 …See details»
ジャパン・ティッシュエンジニアリングと VC Cell - vcct.jp
以下「VCCT」）は、VCCT が有効性と安全性の向上が期待できる新たな技術を用いて開発を 進めている、網膜変性疾患に対するiPS細胞を用いた再生医療製品（開発名:「MastCT-03」） …See details»